Respiratory Syncytial Virus Vaccines Market (By Type: Passive Immunization, Preventive Vaccines; By Technology; By Targeted Population; By Distribution Channel) - Global Industry Analysis, Size, Share, Growth, Trends, Revenue, Regional Outlook and Forecast 2025-2034

Respiratory Syncytial Virus Vaccines Market Size, Share, Report 2025-2034

The global respiratory syncytial virus vaccines market size was worth at USD 3.55 billion in 2024 and is estimated to reach USD 5.05 billion in 2025 to around USD 120.86 billion by 2034, growing at a CAGR of 42.3% from 2025 to 2034. The high disease burden and public awareness, advancement in vaccine technology, and expanding vaccination program and regulatory supports, expansion of the market growth. 

Key Pointers

• By region Asia Pacific region dominated the market with highest share of 31% in 2024.
• By type, the passive immunization segment generated the maximum market share of 76% in 2024. 
• By type, the preventive vaccines segment is expected to grow at the notable CAGR of 49.53% during the forecast period.
• By technology, the monoclonal antibodies segment registered the maximum market share in 2024.
• By technology, the recombinant protein combined with adjuvant segment is expected to grow at the notable CAGR from 2025 to 2034.
• By targeted population, the Infants and children segment captured the maximum market share of 76% in 2024.
• By targeted population, the adult segment is estimated to expand the fastest CAGR during the forecast period.
• By distribution channel, the hospital and retail pharmacies segment contributed the largest market share of 54% in 2024.
• By distribution channel, the government suppliers segment is expected to grow at the fastest CAGR from 2025 to 2034.

Respiratory Syncytial Virus Vaccines

The biological preparations are designed to stimulate the body's immunity system to produce protection against respiratory syncytial virus infection. The market growth is driven by the increasing prevalence of RSV infections and, expanding targeted population in the world. The ongoing trials for material immunization, pediatric vaccines, and the immunocompromised population create opportunities to broaden the addressable market. The increasing awareness and preventive healthcare focus.

Rising Prevalence of RSV Infections of Market Growth.

The increasing burden of RSV is fueling demand for an effective vaccine, with limited treatment options and a high risk of complications, such as bronchiolitis and pneumonia. Preventive vaccination is becoming increasingly critical. The growing prevalence has attracted strong R&D focus from pharmaceutical companies, leading to the development of several RSV vaccines targeting various populations. A growing number of cases increases the need for preventive measures to alleviate this burden.

• In July 2025, the CDC's RSV Vaccine Guidance for Adults, updated, reflects significant changes aimed at broadening vaccine access, simplifying eligibility, and incorporating new product information and safety warnings. (Source: CDC)

Report Scope of the Respiratory Syncytial Virus Vaccines Market

What are the Trends in Respiratory Syncytial Virus Vaccines Market?

Adoption of Novel Vaccine Platforms: The development of recent RSV vaccines, building on lessons from the COVID-19 pandemic, to accelerate research and approvals. The RSV vaccine market now features innovative technologies like messenger RNA (mRNA), recombinant protein subunits, and monoclonal antibodies (mAbs), which offer improved safety and effectiveness for different high-risk populations. 

• In May 2024, the FDA approved Moderna's mRNA-based RSV vaccine, mRESVIA, for adults 60 and older. This demonstrated the successful application of the platform to a disease with a historically challenging vaccine development path. (Source: modernatx)

Market Opportunity

Expansion into Paediatric and Maternal Immunization for the Respiratory Syncytial Virus Vaccines Market

The experience has robust expansion into paediatric and maternal immunization, driven by recent regulatory approvals and the significant disease burden in these populations. This growth is supported by key events such as FDA approvals and updated guidance from public health agencies.

• In June 2025, maternal vaccines could prevent an estimated 2.6 million severe RSV cases in infants across 131 LMICs over nine years, with the WHO prequalifying Abrysvo for global use. (Source: access to medicine foundation)
  

Market Challenge

Protection Gaps in Older Infants of the Respiratory Syncytial Virus Vaccines Market

The maternal vaccines and monoclonal antibodies protect infants in their first few months; efficacy wanes after six months. This leaves older infants, who still face a significant risk of severe RSV, without a prevention strategy.

Which Region Dominates the Respiratory Syncytial Virus Vaccines Market?

The Asia Pacific region held the largest share of the Respiratory Syncytial Virus (RSV) vaccines market, accounting for 31% of the total revenue in 2024. The growing awareness about the severity of RSV infections. Expansion of healthcare facilities and infrastructure is helping with vaccine distribution and accessibility. High rates of respiratory diseases and large birth cohorts in countries such as China and India boost demand for RSV vaccines and therapeutics.

China Respiratory Syncytial Virus Vaccines Market Trends

China has the world's largest pediatric population, a key target group for RSV vaccines, especially monoclonal antibodies for infants. The high dosage burdens government initiatives, and expenditure approval for RSV vaccines and treatments, such as nirsevimab, helps accelerate market access. Increasing healthcare investments and the expansion of hospital infrastructure expand market growth.

Why is North America dominant in the Respiratory Syncytial Virus Vaccines Market?

North America is dominant in the Respiratory Syncytial Virus Vaccines market during the forecast period. The region's advanced healthcare infrastructure system facilitates the development, approval, and distribution of new vaccines. The major key players in the pharmaceutical and biotechnology industries heavily invest in research and development for RSV vaccines, the prevalence of RSV-related hospitalizations, and severe infections in more at-risk groups, fuel the market growth.

Segmental Insights

Type Insights

Why did the Passive Immunization Segment Dominate the Respiratory Syncytial Virus Vaccines Market?

The passive immunization segment dominated the market, capturing the highest revenue share of 76% in 2024. The infectious initial vaccine development, the success of passive immunization are closely tied to the development of monoclonal antibody (mAb) therapies. Immunity for infants with an immature system, the expansion of long-acting monoclonal antibodies, such as nirsevimab, and passive immunization are gaining significant traction as a targeted approach for vulnerable pediatric populations.

The preventive vaccines segment is anticipated to witness the highest growth, registering a remarkable CAGR of 49.53% during the forecast period. The increasingly high burden risk, growing public and healthcare provider awareness of the serious health consequences of RSV, is driving the demand. The government initiatives and funding contribute to vaccine development and distribution, particularly for high-risk populations, and expand market growth.

Technology Insights

How the Monoclonal Antibodies (mAbs)Segment hold the Largest Share in the Respiratory Syncytial Virus Vaccines Market?

The monoclonal antibodies (mAbs) segment held the largest share of market revenue in 2024. A significant breakthrough in this area is the expansion of long-acting monoclonal antibodies, such as nirsevimab (Beyfortus). With a single dose, nirsevimab can deliver infants with protection that lasts an entire RSV season, greatly simplifying the prevention strategy compared to earlier monthly treatments like palivizumab. Nirsevimab is now recommended for all infants under eight months entering their first RSV season, and for certain high-risk children up to 19 months old entering their second season.

The recombinant protein combined with adjuvant segment is experiencing the fastest growth in the market during the forecast period. The recombinant protein vaccines use only specific viral proteins, like the fusion (F) protein, to trigger an immune response, minimizing exposure to other viral components and potentially reducing the risk of adverse reactions compared to live or inactivated virus vaccines. Their strong immunogenicity, targeted approach, and addressing unmet needs fuel the market growth. 

Targeted Population Insights

How the Infants and Children Segment hold the Largest Share in the Respiratory Syncytial Virus Vaccines Market?

The Infants and children dominated the market in 2024, accounting for the highest revenue share of 76% in 2024. The development and approval of new vaccines for respiratory syncytial virus (RSV) have created a robust and growing market for older adults. Previously overlooked, the impact of RSV on seniors, particularly those with underlying conditions, such as COPD, asthma, and heart disease, is now a major public health priority. With the launch of effective recombinant protein-based vaccines and increased immunization initiatives, this segment is experiencing significant expansion.

The adult segment is experiencing the fastest growth in the market during the forecast period. The adult and immunocompromised individuals high risk of severe RSV infections, and pharmaceutical companies are investing and launching RSV vaccines and antibodies specifically for adults. The increasing awareness among healthcare providers about the serious health benefits of vaccination drives the market growth. 

Distribution Channel Insights

The hospital and retail pharmacies segment captured the largest share of market revenue at 54% in 2024. The hospital pharmacies are often the initial point of distribution for infants and pregnant individuals. They offer streamlined administration within a clinical setting, typically during routine appointments such as prenatal visits, pediatric check-ups, or elderly care. This integration into clinical care makes it easier to track and ensure that the most vulnerable patients are immunized.

The government suppliers segment is experiencing the fastest growth in the market during the forecast period. The governments worldwide provide financial support and regulatory incentives, which accelerate vaccine expansion and ensure their extensive availability to the public. The government is actively procuring RSV vaccination to be integrated into these programs, accelerating regulatory approvals, such as FDA designations and review for RSV vaccines.  

The Respiratory Syncytial Virus Vaccines Market-Value Chain Analysis

R&D: The respiratory syncytial virus vaccines market focuses on targeting the pre-fusion F protein, the first-ever approach to RSV vaccines, long-acting monoclonal antibodies, and live-attenuated vaccines.
Patient Support and Services: The respiratory syncytial virus vaccines market contains awareness campaigns, educational resources for patients and healthcare providers, vaccine access programs, and post-vaccination surveillance to monitor safety and effectiveness
Distribution to Hospitals, Pharmacies: The vaccine procedure, targeted administration, material vaccination, federal program, and convenience and uptake.  

Recent Developments

• In April 2025, the European Commission approved an expanded indication for Pfizer's RSV vaccine, Abrysvo, to include adults aged 18 to 59 years who are at increased risk for RSV disease. Previously, it was only approved 
  for adults 60+ and for maternal immunization during pregnancy.  (Source: Pfizer) 

Top Companies in Respiratory Syncytial Virus Vaccines Market

• GSK plc
• Pfizer Inc.
• AstraZeneca plc
• Moderna, Inc.
• Sanofi S.A.
• Bavarian Nordic A/S
• Novavax, Inc.
• Johnson & Johnson (Janssen Pharmaceuticals)
• Merck & Co., Inc.
• Meissa Vaccines, Inc.

Market Segmentation    

By Type 

• Passive Immunization
• Preventive Vaccines

By Technology 

• Monoclonal Antibodies
• Recombinant Protein + Adjuvant
• mRNA-Based Vaccine
• Virus-Like Particle (VLP)

By Targeted Population 

• Adults
• Infants and children

By Distribution Channel 

• Hospital & Retail Pharmacies
• Government Suppliers
• Others

By Regional 

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • China
  • Japan
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait